Building a Population Laboratory for Pharmacoepidemiologic and Pharmacogenomic Studies in Cancer: Cardiotoxicity following Systemic Therapy for Breast Cancer

This CRN proposal represents the collaborative efforts of four multicenter efforts involving members of the HMO Research Network (HMORN)—the AHRQ-funded HMORN Center for Education and Research in Therapeutics (CERTs), the NHLBI-funded Cardiovascular Research Network (CVRN), the Pharmacogenomics Scientific Interest Group of the HMORN, and the CRN. These networks contribute to and use a common data infrastructure. This project, led by Dr. Edward Wagner (GHC), is creating a population research laboratory to conduct pharmacoepidemiologic and pharmacogenomic studies, and will use this laboratory to examine important questions about the cardiotoxicity of systemic agents used to treat invasive breast cancer. Capacity development will assess the validity of electronic data on chemotherapy infusion; adapt and test alternative strategies for identifying cardiotoxicity using VDW data or other electronic data; explore the feasibility of strategies for assembling biological specimens and collecting DNA samples on study subjects; and add analytic variables for chemotherapy dose, route, and type and cardiotoxicity outcomes data to improve the VDW among the eight participating HMORN sites.

<< Back to the list of CRN projects